Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
12 Aprile 2023
2022 for Chiesi: The Group’s international growth continues
05 Aprile 2023
Restore to Impact - The next healthcare landmark for innovation and future-oriented competencies
01 Marzo 2023
Chiesi Group and Affibody collaborate to develop and commercialize innovative treatments for respiratory diseases
07 Marzo 2023
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease
25 Febbraio 2023
Chiesi Global Rare Diseases Presents Long-Term Results from Phase 3 BALANCE and BRIGHT Studies in Fabry Disease at the 19th Annual WORLDSymposium™ Research Meeting
24 Febbraio 2023
Chiesi Global Rare Diseases Announces FDA Approval of Lamzede® (velmanase alfa-tycv) for Alpha-Mannosidosis
22 Febbraio 2023
Chiesi appoints Giuseppe Accogli as new Group CEO
27 Gennaio 2023
Important recognitions for Chiesi Group from the Carbon Disclosure Project (CDP) and Cerved Rating Agency
17 Gennaio 2023
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
